Myelodysplastic syndromes and
Conditions
Interventions
study group:chemotherapy plus HLA-mismatched donor's hematopoitic stem cells infusion
Sponsors
Bone Marrow Transplantation Center of the First Affiliated Hospital,College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients are diagnosed as AML-MRC and High-risk MDS according to the 2016 WHO diagnostic criteria; 2. Patients are not suitable or not willing to undergo allogeneic hematopoietic stem cell transplantation; 3. Patients are willing to bear the cost of decitabine and does not have decitabine allergy histor; 4. Patients have suitable donor willing to donate stem cells (HLA haploidentical or not matched healthy donors; 5. Patients or legal representative have signed informed consent before clinical study start.
Exclusion criteria
Exclusion criteria: 1. Patients does not meet the diagnostic criteria; 2. patients with severe liver and kidney function, cardiorespiratory insufficiency; 3. uncontrolled or severe infection; 4. there may be a mental illness that may prevent subjects from completing treatment or informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;1 year's OS;2-year OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| partial remission;total response rate;relapse rate; | — |
Countries
China
Contacts
Public ContactJie Sun
Bone Marrow Transplantation Center of the First Affiliated Hospital,College of Medicine,Zhejiang University
Outcome results
None listed